Skip to content
CityAM
Main navigation
Sign Up
  • News
    • Latest News
    • Property
    • Media
    • Technology
    • Retail and leisure
    • Transport and infrastructure
    • Law & professional services
    • Legal Notices
    • Banking
    • Politics
    • CFA Institute Talk
  • Markets & Economics
    • Markets & Economics News
    • Economics
    • Markets
    • The Trend Micro Cybersecurity Knowledge Hub
    • Talk Crypto
    • M&A Talk
  • Crypto A.M.
    • Crypto News
    • Crypto Magazine
    • Crypto AM Summit & Awards 2022
  • Opinion
    • Features
    • Letters
    • The City View
  • Money
    • Jobs and Money News
    • Personal Development
    • Jobs
    • Fintech
    • Money
    • Personal Finance
    • Take control of your finances with these eight services
    • Warwick Business School
  • Unwind
    • Life & Style
    • Sport
    • The Punter
    • The Magazine
    • Travel
    • Sport Business
    • The Punter Podcast
    • Culture
    • Six Nations 2023
    • LIV Golf
    • Aramco Team Series
  • Impact A.M.
    • Impact A.M.
    • DiverCity Podcast
    • Partner Hubs
  • Latest Paper
  • Jobs
  • CityAM Awards 2023
  • Charity

AstraZeneca

  • AstraZeneca: UK-Swedish pharma giant almost doubled exports to Russia after invasion of Ukraine

    Jabs army?

    Anglo-Swedish drugs giant AstraZeneca nearly doubled its exports from Sweden to Russia after the Kremlin launched its full-scale attack on Ukraine, according to a report. Sveriges Radio (SR) – the country’s public service broadcaster – said that the FTSE 100 company had exported 2.2 billion Swedish krona (£174 million) worth of chemicals to Russia from [...]

  • UK lost out on £320m AstraZeneca factory: Hunt ‘disappointed’ after drug giant choses low-tax Ireland instead

    hunt

    Chancellor Jeremy Hunt said he was disappointed the UK “lost out this time” on a £320 million new AstraZeneca factory after the drugs giant chose the low-tax Republic of Ireland instead. The group had wanted to build a plant near its existing sites close to Macclesfield, Cheshire, but the “discouraging” tax rate had prompted a [...]

  • Astrazeneca’s shares rise, as cancer drug uptake offsets fall in sales of pharma giant’s Covid-19 vaccine

    Pharma results

    Astrazeneca has posted what it claimed were “strong” financial results for the full year 2022 as surging demand for cancer medicines offset a fall in Covid vaccine revenues. Shares in Astrazeneca jumped on the news as the firm said it expects another year of double-digit revenue growth in 2023. The British firm’s strong results came [...]

  • Drug developer files patents for cancer treatment which ‘outperforms’ AstraZeneca offering

    December 20, 2022

    Drug development company Nuformix has reformulated and improved one of AstraZeneca’s top cancer drugs, piquing investor interest today. Shares in the London-listed firm jumped nearly a quarter to 35p per share by early afternoon on Tuesday. Nuformix, which focuses on fibrosis and cancer drug repurposing, announced that the drug, known as Olaparib, had “outperformed” AstraZeneca’s [...]

  • European regulator injects hope into AstraZeneca’s bid to tackle cancer

    December 19, 2022

    The European Medicines Agency has handed AstraZeneca a number of recommendations and one approval for a trio of cancer drugs the Big Pharma firm is looking to market in the continent. AstraZeneca’s cancer drug Enhertu has been given the green light by the European regulator for use among patients with gastric cancer. Around 136,000 cases [...]

  • AstraZeneca buys therapy firm Neogene for £266m in latest bid to tackle cancer

    November 29, 2022

    AstraZeneca has bought cancer cell therapy company Neogene Therapeutics for $320m (£266m), in the company’s latest investment in its oncology offering. The deal, which is set to close in the coming months, will see AstraZeneca pay $200m as cash in hand, and another $120m if Neogene meets certain milestones. The British-Swedish pharmaceutical giant, behind one [...]

  • Drug developer C4X shares fly after signing £330m AstraZeneca licensing deal

    November 28, 2022

    Drug developer C4X Discovery has signed an exclusive licensing agreement worth up to $402m (£334m) with pharma giant AstraZeneca to develop oral therapy to treat inflammatory diseases. London-listed C4XD’s shares have rocketed this morning, up nearly 40 per cent to 28.5p so far. As part of the deal, C4XD will receive pre-clinical milestone payments worth up [...]

  • AstraZeneca’s battle against cancer knocks on door of EU with three new drugs

    November 14, 2022

    AstraZeneca, the pharmaceutical giant behind one of the world’s first Covid-19 vaccines, has had three new cancer drugs recommended for approval in the European Union. The FTSE 100 pharma firm said its drug Imfinzi – for uses against biliary tract cancer alongside chemotherapy, gastric cancer medicine Enhertu and prostate cancer treatment Lynparza, in combination with [...]

  • AstraZeneca boss urges UK government to invest in medicines of the future

    November 10, 2022

    The chief of AstraZeneca has urged the UK government to invest in the medicines of the future, as the regulatory environment for pharma in the US grows tougher. With the UK’s upcoming budget, CEO Pascal Soriot called on the government to protect the funding for innovative treatments as the long-term outlook for the healthcare industry [...]

  • Investors bet on AstraZeneca’s experimental breast cancer drug following positive trial

    October 26, 2022

    Shares rose in AstraZeneca today on the back of progress made with its breast cancer treatment, which combines its older Faslodex drug with a new experimental offering. Breast cancer is the most common cancer in the world, with around 2.3 million patients diagnosed with the disease in 2020. It follows a disappointing result in a [...]

Posts navigation

  • Page 1
  • Page 2
  • Page 3
  • …
  • Page 20
  • Next

Trending Articles

  • UK recession still on the cards after aggressive Bank of England interest rate hikes

  • HSBC bows to Hong Kong shareholder pressure and tables Asia breakup vote

  • Brexit deal DONE: Sunak's Windsor Framework signed off as UK and EU look for better relationship

  • Four day week? Sure - but you better be in on a Monday, say bosses

Subscribe

Subscribe to the City A.M. newsletter to have our top stories delivered directly to your inbox.

Subscribe
  • About us
  • Advertising
  • Contact
  • Terms & Conditions
  • Privacy Policy
  • News
  • Markets & Economics
  • Opinion
  • Jobs and Money
  • Unwind
  • Crypto A.M.
  • The Punter
  • COP 26
  • Awards 2023

Follow us for breaking news and latest updates

  • Newsletters
  • Latest paper
  • Advertising
  • CryptoAM.io
  • Awards
  • About
  • Tickets
Copyright 2023 City A.M. Limited